Bottom line
The menstrual cycle is a monthly "conversation" between the ovaries and the brain. Whether that cycle is regular is itself a health signal 4.
Menopause occurs on average at 51 to 52. Perimenopause, the transition when hormones start to disorder, can begin 7 to 10 years earlier 5. Estrogen swings high and low, cycles run long and short, and no blood test diagnoses it. Diagnosis rests on symptoms and on ruling other diseases out 5.
The reputation of hormone therapy was dragged for years by a misreading of a large 2002 trial. Later analysis showed that the absolute size of the risk depends heavily on when it is started. People who start within ten years of menopause, and before age 60, have a more favorable balance of benefit and risk 210.
Strength training, protein, sleep, and weight management are the base at every stage, with or without hormone therapy. The views agree 35.
What it is
Each month the ovary and the uterine lining complete one round of preparation. Estrogen and progesterone rise and fall with the cycle, preparing an egg's release and the lining for a possible implantation. If there is no pregnancy, the lining sheds and menstruation follows. The beat the two hormones keep is the background of whether a cycle is regular 4.
Perimenopause is the transition. Dr. Haver calls it a "zone of chaos": estrogen peaks and troughs both higher and lower than in the reproductive years, and unpredictable cycles. Because the swings are so violent, "we do not have a good blood test for perimenopause." Diagnosis rests on symptoms and on ruling other diseases out 5.
The marker of menopause is 12 months without menstruation. The ovary's egg store is used up, and estrogen falls from a cycle into a low line. That low level is continuous, which is why its reach is wide 5.
Symptoms run from hot flashes and night sweats to lighter sleep and mood swings. Genitourinary syndrome — dryness and discomfort — deepens over the years. The later bill is bone and cardiovascular risk 510.
The timing window is the key. The same hormone preparation, started within ten years of menopause and before age 60, does not carry the same risk picture as one started years later. That reading of the Women's Health Initiative is written into the 2022 North American Menopause Society position statement 210.
Why it matters
Cardiovascular disease is the leading cause of death in women, and an American Heart Association statement calls the menopause transition a period of accelerating risk: sex hormones change in a distinctive pattern, and body composition, lipids, and vascular markers shift unfavorably. Midlife is a window for early intervention 11.
Bone is the second bill. Haver cites figures that about half of women face an osteoporotic fracture in a lifetime, and a hip fracture hits older adults hard. Estrogen protects bone. After menopause that defense is withdrawn 5. The 2022 position statement calls hormone therapy the strongest treatment for hot flashes and genitourinary syndrome, and a way to prevent bone loss and fracture 10.
The Women's Health Initiative is the trial behind the reputation. It assigned 16,608 women ages 50–79 who had a uterus to oral estrogen plus progestin or to placebo, and it stopped early, after a mean 5.2 years, on a breast-cancer signal. The media story that hormone therapy is dangerous led a generation of women to stop and endure. The numbers are in the evidence section below 92.
Manson, a principal investigator, re-read it in an interview. Mean age at entry was 63, menopause already more than ten years behind, so the design could not answer what happens in a woman who has just reached menopause. Her line: "the absolute risks of these hormones are much lower in early menopause" 2.
With the epigenetic researcher Morgan Levine, menopause and obesity were discussed as possible accelerators of biological age 7. Breastfeeding is a separate hormone story. Women who breastfeed return to pre-pregnancy weight faster and have lower breast and ovarian cancer risk. In the United States about eight in ten newborns start on breast milk, and about two in ten are still exclusively breastfed at six months. The path needs support, not blame 6.
Different perspectives
Main positions
Hormone therapy is taken up across multiple conversations and essays 1. The conversation with Manson is the weightiest part. They take the Women's Health Initiative apart: enrollment skewed older, menopause already years behind, the breast-cancer detail, and the point that risk or benefit depends on timing and on the person. The dissatisfaction with the one-cut story in mass media is stated explicitly 2.
The conversation with Abbie Smith-Ryan fills in lifestyle. Puberty and menstruation shape performance and recovery. Training and nutrition shift with cycle phase. Inside the perimenopause window, lifestyle levers have long value. Her line is that we "take advantage of lifestyle behavior changes" for a lifelong effect on healthspan 3. The frame is two legs: recalibrating what that trial actually said, and a foundation of training, nutrition, and sleep 23.
One topic page defines female sexual health as a continuum of fertility, hormones, and sexual function, across the cycle, menopause, and after 4. Hormone swings can lead to sexual dysfunction. The estrogen drop of menopause can cause dryness and discomfort, and hormone therapy started close to menopause can improve those symptoms and outcomes 4.
The set piece is gynecologist Mary Claire Haver. She covers the biology, the symptoms, and effects on body composition, cardiometabolic health, and mood. Her tool list is nutrition, resistance training, sleep, and hormone therapy when it is needed 5. Perimenopause has no reliable blood test. Symptoms are the main basis. She describes a patient who went 18 months before a diagnosis, and she says this generation of doctors received very little menopause education 5. She also covers an osteoporosis prevention package, contraception, polycystic ovary syndrome, and hormone therapy next to breast cancer and the heart. The attitude is to lay the evidence out, not to decide for someone 5.
Related material sits in a few cuts. With Morgan Levine, menopause and obesity are discussed as possible accelerators of epigenetic age, and so are the limits of different measuring tools 7. Mark Mattson says there is no human evidence that intermittent fasting harms female fertility or hormone balance. In rats it does not disrupt the estrous cycle, but extreme calorie restriction stops the cycle. Fasting raises stress hormones, and that acute stress is not chronic stress that has gotten away. The safety of fasting in adolescent girls has not been studied at all 8. The breastfeeding page reviews milk and the benefits for mother and infant: a "compensatory immune system" for the baby, and for the mother a faster postpartum recovery and a lower risk of breast and ovarian cancer 6. The stance is consistent. The evidence gap in female physiology is large. Do not slide data from men, or from animals, straight across 78.
Where views agree and differ
Agreement is fairly solid. Perimenopause symptoms are a real physiologic process, worth evaluation and treatment, not something to endure until it passes 510. Hormone therapy has a timing window: within ten years of menopause and before age 60, the balance is more favorable; started late, absolute risk of coronary disease, stroke, clots, and dementia is higher 210. Strength training, protein, and sleep are the foundation at every stage, and perimenopause is still in time 35.
The split is posture. Haver's side would offer hormone therapy more readily to women troubled by symptoms, and questions how little medical education covers menopause 5. Manson's side reads the trial as a lesson in absolute risk, timing, and preparation. Hormone therapy is an individualized decision, not a default 2. The North American Menopause Society statement sits in the middle: the strongest treatment of symptoms, with benefits and harms reassessed on a schedule 10.
Fasting is the other split. Mattson says there is no human evidence of harm to fertility or hormones, and the human studies, including in adolescent girls, have not been done 8. Abbie and Haver put resistance training and protein on the table, and Abbie's notes describe the body-composition and metabolic changes of perimenopause 35.
PearHealth's synthesis
Three things we adopt: evaluation driven by symptoms, not by a blood test; an individualized hormone decision inside the timing window; and strength training plus nutrition as a base that is never absent 5103.
Two things we hold back. Hormone therapy is not a preventive drug for cardiovascular disease or dementia. Hip fracture did fall in the trial, and that is not the same claim 910. Compound "menopause" supplements on the market are not in the same league, and none of these accounts lists them as first-line 510.
The window itself is the point. Body composition, lipids, and vascular health turn during this stretch. The American Heart Association calls it a key window for early intervention, and lifestyle capital put down then compounds the longest 11. Whether to use hormone therapy, for how long, and in which preparation, is a matter between each woman and her doctor 210.
How strong is the evidence
Randomized trials, groups differing only in the thing under study:
- The estrogen-plus-progestin arm of the Women's Health Initiative: 16,608 women, a mean of 5.2 years. Hazard ratios for coronary heart disease, stroke, breast cancer, and pulmonary embolism were about 1.3, 1.4, 1.3, and 2.1. Hip fracture and colorectal cancer fell. Total death did not differ. The absolute gaps are item by item: 7 extra coronary events per 10,000 person-years, and 8 extra each for stroke, pulmonary embolism, and invasive breast cancer. A doubled relative risk sounds frightening. The absolute numbers are a different story 9.
- Its limits are equally clear: a particular oral preparation, and enrollment skewed older (mean age 63, more than ten years past menopause). Extrapolation to a woman who has just reached menopause is limited 2.
A society position statement, an expert's systematic reading of the evidence:
- North American Menopause Society, 2022: hormone therapy is the strongest treatment for vasomotor symptoms. Started before age 60 or within ten years of menopause, the balance of benefit and risk is favorable. Later than that, absolute risk rises. Benefits and harms are reassessed on a schedule 10.
A scientific statement, a pooling of longitudinal cohorts:
- American Heart Association, 2020: across the menopause transition, sex hormones show a distinctive pattern of change, and body composition, lipids, and vascular markers shift unfavorably. The stretch is a period of accelerating cardiovascular risk, and it is also a window for intervention 11.
Observational evidence, association rather than cause:
- The links between breastfeeding and a lower risk of breast and ovarian cancer in the mother, and a faster postpartum recovery, come from epidemiologic studies, with healthy-user confounding present 6.
Expert experience, a personal clinical view, not a trial result:
- Haver's statement that perimenopause has "no reliable blood test, diagnosis by symptoms," and Abbie's observations on training, sit at the level of experience and mechanistic inference. The direction does not conflict with the evidence above 53.
What you can do
Directions many people take:
- Keep a record of the cycle: length, flow, symptoms. Diagnosis of perimenopause rests on that record. At a visit it is the best evidence 5.
- When hot flashes, night sweats, worsening sleep, and a slide in mood arrive as a string, talk with a gynecologist early. Do not default to "the only option is to endure it" 510.
- Put resistance training on the weekly calendar, eat enough protein, and put sleep first. That is the investment with the longest return inside the perimenopause window 35.
- At a midlife checkup, give an extra look to lipids, body composition, waist, and blood glucose. The menopause transition is the stretch in which these markers turn 11.
- Pay attention to bone density. With a family history of fracture, or with early menopause, discuss the timing of a bone-density test with a doctor 5.
- A mother who is breastfeeding seeks lactation guidance as she needs it. When it is hard, she looks for skilled help rather than pushing through alone 6.
- Keep a clear head about intermittent fasting. Evidence at the level of women is limited. In this stage, holding on to muscle and bone comes first 83.
Questions worth raising with a doctor:
- Do my symptoms look like perimenopause? Is it worth checking the thyroid and other causes that get confused with it first? 5
- Am I inside the timing window? What shape do the benefits and harms of hormone therapy take for me? 102
- I have a uterus. How is the progestin part of a hormone plan arranged? 10
- Do my bone density and my lipids need a baseline check now? 511
- I am breastfeeding, or I plan to. What do my medicines and my nutrition need to take into account? 6
Common misconceptions
Misconception one: menopause is the business of the day periods stop. The transition can start 7 to 10 years earlier. Changes in mood, sleep, and the cycle often appear years before periods end 5.
Misconception two: a blood test can diagnose perimenopause. Haver's statement is that the transition has no good blood test. Diagnosis rests on symptoms and on ruling out other diseases. The lab slip is a supporting player 5.
Misconception three: the Women's Health Initiative proved that hormone therapy is harmful to women. What it showed is the balance of benefit and harm of a particular oral preparation in a group of women whose mean age was 63 and whose menopause was already more than ten years behind them. Change the timing and the preparation, and the conclusion changes 29.
Misconception four: hot flashes are a small matter, and enduring them is enough. Moderate to severe hot flashes erode sleep and quality of life, and hormone therapy is the strongest symptomatic treatment. Started inside the window, the chance that benefit outweighs harm is higher 10.
Misconception five: once a person is older, strength training is no longer useful. The opposite is closer to the case. From perimenopause into the years after menopause, the loss of muscle and of bone speeds up, and the marginal value of resistance training and of protein is highest in this stage 35.
How it connects to your blood work
Female hormone markers can barely be read apart from the phase of the cycle and the stage of life. This section only says, roughly, what each item is looking at.
- Estradiol (estradiol): the main estrogen. Read it against cycle phase. A single perimenopause value is very noisy 5.
- Progesterone (progesterone): prepares and maintains the lining, which sheds as menstruation if there is no pregnancy. A single result needs the cycle phase 4.
- Follicle-stimulating hormone (fsh): the pituitary's call to the ovary. Haver describes stronger FSH pulses in perimenopause, and a single result still cannot settle the question 5.
- Anti-Müllerian hormone (amh): remaining egg store, used mainly for fertility. It cannot forecast the date of menopause.
- Thyroid-stimulating hormone (tsh): thyroid problems can imitate perimenopause symptoms. Haver lists the thyroid as something to look at alongside 5.
- Total testosterone, female (testosterone-total-female): women have testosterone too, tied to desire and muscle. The episode also covers polycystic ovary syndrome 5.
- DHEA sulfate, female (dhea-s-female): an adrenal precursor. Haver discusses a vaginal DHEA preparation for genitourinary symptoms. That is a local preparation, not this blood test 5.